Replies to post #177222 on Biotech Values

[jq1234]

WSJ article's take on GSK/NVS/LLY deal:

Deal Flurry Shows Drug Makers' Swing Toward Specialization

After Decades of Broadening Portfolios, Pharmaceutical Companies Narrow Focus

http://online.wsj.com/news/articles/SB10001424052702303825604579518054271953092?mod=rss_Health&mg=reno64-wsj

GSK says it will continue research on immunotherapy, epigenetics, and tumor environment. How does that work as the deal allows NVS to opt-in any oncology drug in GSK pipeline? What incentive does GSK have to continue further? It will remain to be seen what GSK does with some of its partnered early assets. There might be some small partners feeling uneasy at the moment. Same is true for some of NVS small partners.